Clinical Trial Update: IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US [Phase 4]

View source ↗

Summary

Phase 4 clinical trial IKANOS evaluating Breztri maintenance versus non-triple inhaled therapy after COPD hospitalization has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Breztri (budesonide/glycopyrronium/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: COPD | Phase 4 | Status: WITHDRAWN